Rheumatoid Arthritis News

SAN DIEGO — In this video, Jeffrey A. Sparks, MD, MMSc, spoke with Healio about the safety of TNF inhibitors compared with alternative targeted therapies for patients with rheumatoid arthritis-associated interstitial lung disease.

Patients receiving the adalimumab biosimilar SB5 demonstrated high persistence, consistent effectiveness and no new safety signals through 48 weeks, according to data published in BioDrugs.

SAN DIEGO — In this Healio video, Jeffrey A. Sparks, MD, MMSc, discusses results from a proof-of-concept study that assessed the efficacy of administering medication for rheumatoid arthritis into the peripheral lymphatic systems.

SAN DIEGO — Jeffrey A. Sparks, MD, MMSc, spoke with Healio about two “high-impact” presentations from ACR Convergence 2023 that assessed dosing of prednisone for patients with rheumatoid arthritis.

SAN DIEGO — In this video, Healio spoke with Jeffrey A. Sparks, MD, MMSc, results from a study conducted in India assessing the efficacy of treating rheumatoid arthritis with split-doses of methotrexate.

SAN DIEGO — The likelihood of opioid use among patients with autoimmune rheumatic disease has decreased annually by 15% since 2014, according to data presented at ACR Convergence 2023.

The FDA has advised consumers to exercise caution before using certain products promoted for arthritis and pain, as some have been found to contain hidden ingredients that may pose a significant health risk.

SAN DIEGO — Glucocorticoid doses as small as 5 mg per day, in durations as short as 30 days, and a use period as long as 1 year all increase the risk for major adverse cardiac events in rheumatoid arthritis, said a speaker here.

In this episode of Meeting Mic, we bring you Healio’s top headlines from ACR Convergence 2023.

SAN DIEGO — An automated deep learning model accurately identified and predicted joint space narrowing and erosion based on hand radiographs of patients with rheumatoid arthritis, according to data presented at ACR Convergence 2023.